[Extracorporeal circulation with danaparoid sodium for valve replacement in thrombocytopenia induced by type II heparin]

Ann Fr Anesth Reanim. 2001 Nov;20(9):799-802. doi: 10.1016/s0750-7658(01)00487-7.
[Article in French]

Abstract

A type II heparin-induced thrombocytopenia (HIT) was diagnosed in a 64-year-old woman at day 20 of intravenous unfractionated heparin (UFH) therapy, given after myocardial infarction treated by angioplasty and intracoronary stent. The infarction was complicated by a mitral insufficiency that led to a mitral valve replacement. Cardiopulmonary bypass was successfully performed with sodium danaparoid (Orgaran), as an alternative to UFH, without thrombotic or haemorrhagic complications and the follow-up was uneventful.

Publication types

  • Case Reports

MeSH terms

  • Anticoagulants / therapeutic use*
  • Chondroitin Sulfates / therapeutic use*
  • Dermatan Sulfate / therapeutic use*
  • Drug Combinations
  • Extracorporeal Circulation*
  • Female
  • Heart Valve Prosthesis*
  • Heparin / adverse effects*
  • Heparitin Sulfate / therapeutic use*
  • Humans
  • Middle Aged
  • Mitral Valve Insufficiency / complications
  • Mitral Valve Insufficiency / surgery*
  • Thrombocytopenia / chemically induced*
  • Thrombocytopenia / complications

Substances

  • Anticoagulants
  • Drug Combinations
  • Dermatan Sulfate
  • Heparin
  • Chondroitin Sulfates
  • Heparitin Sulfate
  • danaparoid